The infrastructure for GLP-1 adherence

The clinical shift in obesity management has moved from willpower-based narratives to pharmaceutical interventions, specifically GLP-1 receptor agonists. While these medications are effective, they present a logistical challenge for the healthcare system: how to manage millions of patients on chronic, expensive, and side-effect-prone treatments. Boli Care is building a digital therapeutic platform designed to close this gap. Based in Biarritz, France, the company functions as a companion layer between the patient, the physician, and the pharmaceutical manufacturer.

The core of the product is a digital therapeutic (DTx) platform that tracks patient insights and clinical evidence in real-time. This is not a fitness tracker or a calorie counter. Instead, Boli Care focuses on the metabolic and behavioral data generated by patients during their treatment journey. By analyzing real-world metabolic data, the platform attempts to understand patient outcomes and drug effectiveness outside of controlled clinical trials.

Modeling the metabolic response

Boli Care differentiates itself by positioning its software as a scientific engine rather than a lifestyle app. Their internal teams, including clinical data scientists, build predictive models for treatment adherence and side-effect prediction. These models allow the platform to identify which patients are likely to stop their medication early or which are experiencing side effects that require clinical intervention.

For healthcare providers in France, including specialized obesity centers (CSO) and university hospitals (CHU), the platform is a remote monitoring tool. It allows medical teams to oversee larger patient populations without increasing the frequency of in-person visits. This is a critical requirement in the French healthcare system, where medical resources are often stretched thin and the adoption of digital tools is increasingly tied to regulatory evidence.

Real-world evidence and pharmaceutical partnerships

Beyond patient care, Boli Care is a data company. It partners with pharmaceutical organizations to generate real-world evidence (RWE). In the pharmaceutical industry, RWE is becoming a currency for justifying drug pricing and proving long-term efficacy to insurers. Boli Care collects and models behavioral and metabolic datasets to provide these insights, bridging the distance between a patient’s daily life and a pharmaceutical company’s research needs.

Founded by Paul-Louis Belletante, the company reflects a broader trend in the European healthtech sector: the move toward highly regulated, clinically validated software. They maintain compliance with ISO 13485 and GDPR, reflecting the necessity of meeting medical device standards in the EU. This regulatory focus makes them a more viable partner for public health institutions than many of their consumer-facing competitors.

The transition to automated metabolic care

The long-term value of Boli Care lies in its ability to personalize care at scale. As they aggregate more data on GLP-1 responses, their models move from descriptive to prescriptive. The platform can suggest specific lifestyle adaptations or timing for injections based on a patient’s unique metabolic profile. This represents a shift toward a more automated form of obesity care—where software handles the routine management of the disease, leaving only the most complex cases for human specialists.